Background: Advanced liver disease is known to increase the risk for bleeding and affects
the hepatic clearance and metabolism of drugs. Subjects with active liver disease were …

Background A complication of chronic liver disease (CLD) is the abnormality of coagulation.
In clinical practice, this increased risk of bleeding has not been identified as a protective …

Background: The benefit-risk profile of direct oral anticoagulants (DOACs) compared with
warfarin, and between DOACs in patients with atrial fibrillation (AF) and chronic liver disease …

Patients with liver disease are at increased risks of both thrombotic and bleeding
complications. Many have atrial fibrillation (AF) or venous thromboembolism (VTE) …

Background: Patients with liver disease have increased risk of thrombosis and bleeding but
are typically excluded from trials of direct oral anticoagulant agents. Objectives: This study …

Background Many patients with cirrhosis have concurrent nonvalvular atrial fibrillation
(NVAF). Data are lacking regarding recent oral anticoagulant (OAC) usage trends among …

Background Liver cirrhotic patients with nonvalvular atrial fibrillation have been excluded
from randomized clinical studies regarding oral anticoagulants for stroke prevention …

Background Patients with impaired liver function (ILF) were excluded from clinical trials that
investigated non–vitamin K antagonist oral anticoagulants (NOAC s) for stroke prevention in …

Summary Background Direct oral anticoagulants (DOACs) are widely used as an alternative
for warfarin. However, the impact of DOACs on mortality outcomes compared with warfarin …

Direct oral anticoagulants (DOACs) have been used in clinical practice in the United States
for the last 4 to 6 years. Although DOACs may be an attractive alternative to warfarin in many …